ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Anjo-Roch
|
9.4K |
2.7M |
23 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
23
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Anjo-Roch
|
9.4K |
2.7M |
36 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
9.4K
|
2.7M
|
36
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Anjo-Roch
|
904 |
275K |
37 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
904
|
275K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Anjo-Roch
|
904 |
275K |
21 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
904
|
275K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Anjo-Roch
|
904 |
275K |
11 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
904
|
275K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Anjo-Roch
|
904 |
275K |
12 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
904
|
275K
|
12
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Anjo-Roch
|
904 |
275K |
30 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
904
|
275K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
CEO Itescu needs to go
|
|
Anjo-Roch
|
904 |
275K |
42 |
06/08/23 |
06/08/23 |
ASX - By Stock
|
904
|
275K
|
42
|
|
ASX - By Stock
|
MSB |
Re:
2023 The Final Countdown
|
|
Anjo-Roch
|
3.4K |
1.1M |
40 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
3.4K
|
1.1M
|
40
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESO watch and banter
|
|
Anjo-Roch
|
400 |
148K |
5 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
400
|
148K
|
5
|
|
ASX - By Stock
|
MSB Biotech |
Re:
MESO watch and banter
|
|
Anjo-Roch
|
400 |
148K |
21 |
18/07/23 |
18/07/23 |
ASX - By Stock
|
400
|
148K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Third Quarter Results Presentation
|
|
Anjo-Roch
|
55 |
21K |
20 |
30/05/23 |
30/05/23 |
ASX - By Stock
|
55
|
21K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
banter and General Discussion
|
|
Anjo-Roch
|
9.4K |
2.7M |
23 |
28/09/22 |
28/09/22 |
ASX - By Stock
|
9.4K
|
2.7M
|
23
|
|
ASX - By Stock
|
MSB |
Re:
rurenga
|
|
Anjo-Roch
|
62 |
22K |
21 |
28/03/22 |
28/03/22 |
ASX - By Stock
|
62
|
22K
|
21
|
|
ASX - By Stock
|
GTG |
Re:
Ann: Genetic Technologies 1H FY22 results
|
|
Anjo-Roch
|
4 |
1.5K |
4 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
4
|
1.5K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on Novartis Agreement
|
|
Anjo-Roch
|
850 |
249K |
40 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
850
|
249K
|
40
|
|
ASX - By Stock
|
MSB |
Re:
Growing doubt on COVID-19 Application
|
|
Anjo-Roch
|
4.7K |
1.0M |
44 |
03/12/21 |
03/12/21 |
ASX - By Stock
|
4.7K
|
1.0M
|
44
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Anjo-Roch
|
5.0K |
2.4M |
64 |
11/09/21 |
11/09/21 |
ASX - By Stock
|
5.0K
|
2.4M
|
64
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Partnership Announcements
|
|
Anjo-Roch
|
90 |
32K |
18 |
20/02/21 |
20/02/21 |
ASX - By Stock
|
90
|
32K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
MSB Valuation
|
|
Anjo-Roch
|
179 |
51K |
59 |
17/02/21 |
17/02/21 |
ASX - By Stock
|
179
|
51K
|
59
|
|
ASX - By Stock
|
MSB |
Re:
MPC-06-ID Phase 3 results countdown
|
|
Anjo-Roch
|
273 |
140K |
49 |
01/02/21 |
01/02/21 |
ASX - By Stock
|
273
|
140K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Let's get the readings on the 28th of Dec
|
|
Anjo-Roch
|
8 |
4.7K |
55 |
24/12/20 |
24/12/20 |
ASX - By Stock
|
8
|
4.7K
|
55
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Webcast
|
|
Anjo-Roch
|
183 |
94K |
37 |
18/12/20 |
18/12/20 |
ASX - By Stock
|
183
|
94K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading halt
|
|
Anjo-Roch
|
796 |
393K |
49 |
16/12/20 |
16/12/20 |
ASX - By Stock
|
796
|
393K
|
49
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
Anjo-Roch
|
344 |
178K |
50 |
11/12/20 |
11/12/20 |
ASX - By Stock
|
344
|
178K
|
50
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
Anjo-Roch
|
5.0K |
2.4M |
17 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
5.0K
|
2.4M
|
17
|
|
ASX - By Stock
|
LOM |
Re:
Ann: Trading Halt
|
|
Anjo-Roch
|
204 |
67K |
25 |
09/12/20 |
09/12/20 |
ASX - By Stock
|
204
|
67K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Mesoblast Phase 3 CLBP Trial Completes Enrollment
|
|
Anjo-Roch
|
272 |
108K |
37 |
04/12/20 |
04/12/20 |
ASX - By Stock
|
272
|
108K
|
37
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
|
|
Anjo-Roch
|
572 |
250K |
90 |
02/12/20 |
02/12/20 |
ASX - By Stock
|
572
|
250K
|
90
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Anjo-Roch
|
811 |
332K |
113 |
30/11/20 |
30/11/20 |
ASX - By Stock
|
811
|
332K
|
113
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Anjo-Roch
|
811 |
332K |
46 |
25/11/20 |
25/11/20 |
ASX - By Stock
|
811
|
332K
|
46
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Anjo-Roch
|
13K |
4.9M |
51 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
13K
|
4.9M
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Novartis and Mesoblast Remestemcel-L Collaboration
|
|
Anjo-Roch
|
811 |
332K |
79 |
20/11/20 |
20/11/20 |
ASX - By Stock
|
811
|
332K
|
79
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Anjo-Roch
|
13K |
4.9M |
22 |
14/11/20 |
14/11/20 |
ASX - By Stock
|
13K
|
4.9M
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
|
|
Anjo-Roch
|
392 |
157K |
66 |
11/11/20 |
11/11/20 |
ASX - By Stock
|
392
|
157K
|
66
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
Anjo-Roch
|
344 |
178K |
132 |
02/11/20 |
02/11/20 |
ASX - By Stock
|
344
|
178K
|
132
|
|
ASX - By Stock
|
MSB |
Re:
Phase 3 DREAM HF-1 read-out
|
|
Anjo-Roch
|
344 |
178K |
95 |
31/10/20 |
31/10/20 |
ASX - By Stock
|
344
|
178K
|
95
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast Company Update - Webcast and Forward Thoughts
|
|
Anjo-Roch
|
273 |
127K |
20 |
03/10/20 |
03/10/20 |
ASX - By Stock
|
273
|
127K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Anjo-Roch
|
555 |
266K |
66 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
555
|
266K
|
66
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Update on BLA for Graft Versus Host Disease
|
|
Anjo-Roch
|
555 |
266K |
21 |
02/10/20 |
02/10/20 |
ASX - By Stock
|
555
|
266K
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Anjo-Roch
|
635 |
275K |
51 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
635
|
275K
|
51
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Anjo-Roch
|
635 |
275K |
14 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
635
|
275K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Trading Halt
|
|
Anjo-Roch
|
635 |
275K |
111 |
01/10/20 |
01/10/20 |
ASX - By Stock
|
635
|
275K
|
111
|
|
ASX - By Stock
|
MSB |
Re:
MSB Trading 2020 - a new dawn
|
|
Anjo-Roch
|
13K |
4.9M |
21 |
19/09/20 |
19/09/20 |
ASX - By Stock
|
13K
|
4.9M
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Regenerative Medicine and Cell Therapies Virtual Event
|
|
Anjo-Roch
|
129 |
56K |
62 |
18/09/20 |
18/09/20 |
ASX - By Stock
|
129
|
56K
|
62
|
|
ASX - By Stock
|
MSB Biotech |
Re:
New video discussion with Mesoblast CEO
|
|
Anjo-Roch
|
122 |
63K |
93 |
13/09/20 |
13/09/20 |
ASX - By Stock
|
122
|
63K
|
93
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Anjo-Roch
|
26 |
15K |
38 |
07/09/20 |
07/09/20 |
ASX - By Stock
|
26
|
15K
|
38
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Anjo-Roch
|
17K |
6.6M |
41 |
06/09/20 |
06/09/20 |
ASX - By Stock
|
17K
|
6.6M
|
41
|
|
ASX - By Stock
|
MSB |
Re:
News: MSB Mesoblast Says DSMB Recommends Continuation Of Remestemcel-L Phase 3 Trial In Covid-19...
|
|
Anjo-Roch
|
21 |
12K |
132 |
04/09/20 |
04/09/20 |
ASX - By Stock
|
21
|
12K
|
132
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Ethics Approval to Treat COVID-19 Patients in Australia
|
|
Anjo-Roch
|
320 |
129K |
73 |
02/09/20 |
02/09/20 |
ASX - By Stock
|
320
|
129K
|
73
|
|